Isomorphic raises $2B; Odyssey IPOs $304M
- Isomorphic Labs is in advanced talks to raise more than $2 billion, while Odyssey Therapeutics priced an upsized Nasdaq IPO and placement worth $304 million. - The Odyssey deal combined 15.5 million IPO shares at $18 with a TPG-backed private placement, while Thrive Capital is set to lead Isomorphic’s round. - Biotech capital is reopening for bigger, later-stage bets — especially AI drug discovery and clinical assets with a clearer path.
Biotech financing is doing something it has not done cleanly in years — it is reopening for very large checks. This week’s two clearest examples sit at opposite ends of the pipeline. Isomorphic Labs, Alphabet’s AI drug-discovery company, is in advanced talks to raise more than $2 billion. Odyssey Therapeutics, a clinical-stage immunology biotech, priced an upsized IPO and concurrent private placement worth about $304 million. Together, they show what money wants right now: either platform-scale AI with strategic backers, or public-ready drug programs with near-term clinical milestones. ### What is Isomorphic actually raising money for? Isomorphic is not a one-drug biotech. It is trying to build a machine for drug design — using DeepMind-style AI, protein structure tools, and pharma partnerships to generate medicines faster. That is why the number is so striking. A $2 billion-plus round is not normal venture financing for biotech software. It is growth capital for a company trying to become core infrastructure for drug discovery. Thrive Capital is expected to lead, and Alphabet is participating, which matters because this is not just financial sponsorship — it is strategic support from the parent ecosystem. (bloomberg.com) ### Is that $2 billion deal done? Not yet — and that distinction matters. The reporting says Isomorphic is in advanced discussions to raise more than $2 billion, not that the round has already closed. So the signal here is investor appetite as much as completed financing. Even in a better market, a round that size still needs final terms, allocation, and paperwork. But advanced talks at that scale usually mean serious momentum, not casual fundraising chatter. (bloomberg.com) ### What exactly did Odyssey pull off? Odyssey did the more old-school capital-markets version. On May 7, it priced 15.5 million shares at $18 each in an upsized IPO, plus a concurrent sale of 1,388,889 shares to an affiliate of TPG Life Sciences Innovations at the same price. Add those together and gross proceeds land at roughly $304 million, before any underwriter option. That is a big debut for a clinical-stage biotech in a market that only recently stopped acting frozen. (bloomberg.com) ### Why did investors buy this one? Because Odyssey looks like the kind of company public biotech investors have started tolerating again — focused, clinical, and not too early. The company is developing drugs for autoimmune and inflammatory diseases, and it has said the IPO proceeds will help push lead candidate OD-001, a RIPK2 scaffolding blocker, through mid-stage ulcerative colitis studies. Basically, this is not a vague platform story. Investors can see the program, the indication, and the trial path. (investors.odysseytx.com) ### So is biotech “back”? Yes — but only in a selective way. Q1 biotech IPO volume was still slow by count, yet the dollars raised jumped sharply, with about $1.7 billion banked in the quarter. JPMorgan’s Q1 review made the same broader point: financing improved, but capital stayed concentrated in later-stage assets, differentiated science, and programs with clearer clinical or commercial pathways. That is the key. The window is open, but it is not open for everyone. (marketwatch.com) ### Why pair these two deals together? Because they map the new barbell in biotech funding. One side is AI-enabled discovery at enormous scale, where investors are paying for platform leverage and strategic optionality. The other is public-market biotech with identifiable catalysts and enough maturity to survive scrutiny. The middle — early, undifferentiated, story-heavy companies — still looks much tougher. (biopharmadive.com) ### What is the bottom line? Money is flowing again, but it is flowing uphill. If you have a company like Isomorphic, with Alphabet ties and a frontier-AI pitch, investors will entertain a huge private round. If you have a company like Odyssey, with a defined pipeline and a public-market-ready story, you can raise hundreds of millions. Everyone else still has to fight for oxygen. (bloomberg.com)
